MLICM
BBIO icon

Metropolitan Life Insurance Company (MetLife)’s BridgeBio Pharma BBIO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,256
Closed -$193K – 250
2024
Q1 		$193K Sell
6,256
-382
-6% -$13K 0.01% 731
2023
Q4 		$268K Hold
6,638
– – 0.01% 611
2023
Q3 		$175K Buy
6,638
+380
+6% +$10.8K 0.01% 743
2023
Q2 		$108K Buy
6,258
+372
+6% +$5.6K 0.01% 982
2023
Q1 		$97.6K Sell
5,886
-902
-13% -$10.5K 0.01% 1005
2022
Q4 		$51.7K Hold
6,788
– – ﹤0.01% 1449
2022
Q3 		$67.5K Hold
6,788
– – ﹤0.01% 1258
2022
Q2 		$61.6K Hold
6,788
– – ﹤0.01% 1363
2022
Q1 		$68.9K Sell
6,788
-20,117
-75% -$206K ﹤0.01% 1412
2021
Q4 		$449K Sell
26,905
-1,560
-5% -$66K 0.01% 1518
2021
Q3 		$1.33M Sell
28,465
-879
-3% -$47.1K 0.02% 768
2021
Q2 		$1.79M Buy
29,344
+3,861
+15% +$220K 0.03% 583
2021
Q1 		$1.57M Buy
25,483
+4,478
+21% +$293K 0.02% 656
2020
Q4 		$1.49M Hold
21,005
– – 0.02% 625
2020
Q3 		$788K Sell
21,005
-1,692
-7% -$53.2K 0.01% 888
2020
Q2 		$740K Hold
22,697
– – 0.01% 931
2020
Q1 		$658K Buy
22,697
+15,203
+203% +$471K 0.01% 903
2019
Q4 		$263K Sell
7,494
-3,336
-31% -$92.5K ﹤0.01% 1732
2019
Q3 		$233K Buy
+10,830
New +$300K ﹤0.01% 1775

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s BBIO Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of BridgeBio Pharma (BBIO) in Q2 2024, closing a stake of 6,256 shares — an estimated $193K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in BBIO in Q3 2019 and held it in 19 quarters. The position peaked at $1.79M in Q2 2021. 251 funds tracked by Wall St. Rank hold BBIO as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining BridgeBio Pharma position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 6,256 BridgeBio Pharma shares in Q2 2024, an estimated $193K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in BridgeBio Pharma in Q3 2019 and held it in 19 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s BridgeBio Pharma position peaked at $1.79M in Q2 2021.
  • 251 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.